Enfortumab Vedotin 和 Pembrolizumab 进展后的治疗：在新的治疗格局中探索转移性尿路上皮癌的二线选择。
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
发表日期：2024 May 25
作者：
Jason R Brown, Vadim S Koshkin
来源：
European Urology Focus
摘要：
对于使用 enfortumab vedotin 和 pembrolizumab 治疗进展后的转移性尿路上皮癌患者，目前尚无明确的治疗标准，尽管有多种治疗方案可供选择，包括针对选定患者的铂类化疗、sacituzumab govitecan 和 erdafitinib。临床试验对于为最佳治疗决策提供重要信息。版权所有 © 2024 欧洲泌尿外科协会。由 Elsevier B.V. 出版。保留所有权利。
There is no clear standard-of-care treatment for patients with metastatic urothelial carcinoma following progression on enfortumab vedotin and pembrolizumab, although multiple regimens are available, including platinum-based chemotherapy, sacituzumab govitecan, and erdafitinib for selected patients. Clinical trials will be important in informing decisions on the best treatment.Copyright © 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.